Gentibio, Inc.
Cambridge, MA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 150 Cambridgepark Dr Suite 900, Cambridge, MA 02140, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Microquin LTD | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Mellicell, Inc. | Watertown, MA | — |
| Modulo Bio, Inc. | San Diego, CA | — |
| Cartesian Therapeutics Inc. | Frederick, MD | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| General Biologics Inc. | Cambridge, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Gentibio, Inc., a for-profit biopharmaceutical company based in Cambridge, Massachusetts, is a federal grant recipient developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases under research awards from the National Institutes of Health and the Defense Health Agency. The vendor operates exclusively as a prime recipient on federal grants with no contract prime or subcontractor experience in the source data; all three awards are Phase II SBIR-equivalent research grants carrying a combined obligated value of $4.2 million across three distinct federal agencies.
Gentibio's customer base is concentrated among health research grantors. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Neurological Disorders and Stroke (NINDS), and the Defense Health Agency each account for one award. The NIDDK award of $1,066,332 (awarded August 24, 2026, under CFDA 93.847, Diabetes, Digestive, and Kidney Diseases Extramural Research) funds development of GNTI-148, an allogeneic islet-specific engineered Treg therapy for newly diagnosed type 1 diabetes, with performance through July 31, 2028. The Defense Health Agency awarded $825,756 on May 1, 2026 (CFDA 12.420, Military Medical Research and Development) for tissue-engineered Tregs targeting amyotrophic lateral sclerosis, running through June 30, 2028. NINDS issued a grant on August 15, 2025, for development of allogeneic engineered tissue Tregs as an acute ischemic stroke therapy, completing July 31, 2027. All work is performed in Cambridge, Massachusetts.
Gentibio's core capability centers on proprietary platform engineering of allogeneic Treg products, characterized by stable FOXP3 expression, tissue-specific targeting, hypoimmune engineering for allograft tolerance, and tunable IL-2 signaling via chemically inducible signaling complexes. The vendor targets off-the-shelf scalability and cost-effectiveness relative to autologous therapies. All three awards face ultimate completion within the next twenty-four months, creating a recompete window for continued federal funding.
Quick answers
Is Gentibio, Inc. registered in SAM.gov?
Yes. Gentibio, Inc.'s SAM.gov registration is active through May 30, 2027.
What is Gentibio, Inc.'s CAGE code?
Gentibio, Inc.'s CAGE code is 9YYH9, and its Unique Entity ID (UEI) is HNHTFLZ9U5D4.
What is Gentibio, Inc.'s most recent federal award?
Gentibio, Inc.'s most recent federal grant award is Gnti-148: an allogeneic islet-specific engineered treg for treating T1D (R44DK148168), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on August 24, 2026.
On GovTribe
See Gentibio, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors